Alexei Repik News Today

May 15, 2021 Moscow – Transforming the site of what once was a Soviet-era car factory into a state-of-the-art facility churning out Russia’s COVID-19 vaccine Sputnik V was the easy bit. Making doses in bulk, finding qualified staff and getting equipment have been much bigger headaches for Moscow-based biotech firm R-Pharm and other private Russian companies picked to make the country’s flagship shot to fight the pandemic. President Vladimir Putin has trumpeted the vaccine around ...

The problems are a warning to foreign partners – including in India – that are planning to mass produce the vaccine.

President Vladimir Putin has trumpeted the vaccine around the world, and said in March that Russia had signed agreements for the production of 700 million doses of Sputnik V vaccine abroad. But Russia had produced just 33 million vaccines as of May 12 and exported fewer than 15 million.

COVID-19 vaccine: Heres why Russia is struggling to make Sputnik V doses The Russian Direct Investment Fund (RDIF), which is responsible for marketing the vaccine abroad, said the manufacturing capacity for Sputnik V was increasing globally as new manufacturers come on board. Reuters | May 14, 2021 | Updated 14:36 IST Transforming the site of what once was a Soviet-era car factory into a state-of-the-art facility churning out Russias COVID-19 vaccine Sputnik V was the easy bit. Making doses in...

INSIGHT-Big promises, few doses: why Russias struggling to make Sputnik V doses Reuters 3 hrs ago * Russia has touted Sputnik V vaccine around world * Vaccine production and exports lower than expected * Manufacturers face a series of big challenges * Hurdles serve as a warning to foreign partners (Updates to add comment from Russias industry ministry) By Polina Nikolskaya and Polina Ivanova MOSCOW, May 14 (Reuters) - Transforming the site of what once was a Soviet-era car factory into a stat...

Trial combining British and Russian COVID-19 vaccines could begin in February AstraZeneca announced the clinical trial programme in December A clinical trial that will combine AstraZeneca (AZ)/Oxford University’s COVID-19 vaccine with Russia’s Sputnik V COVID-19 vaccine could begin in February, according to the chairman of Russian pharma R-Pharm.  R-Pharm chairman Alexei Repik told Reuters that human trials of the combined vaccination are expected to start in early February, a month after...

Sputnik-AstraZeneca vaccine trials to start in February, says R-Pharm Reuters 19/01/2021 By Polina Nikolskaya © Reuters/JASON CAIRNDUFF FILE PHOTO: A health worker fills a syringe with a dose of the Oxford/AstraZeneca COVID-19 vaccine By Polina Nikolskaya MOSCOW (Reuters) - Human trials of a coronavirus vaccine combining Russias Sputnik V shot with that developed by Britains AstraZeneca and Oxford University are expected to start in early February, the chairman of Russian...